Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

NCT00205478 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Vertex Pharmaceuticals Incorporated